Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Fentanyl for COVID-19 Respiratory Symptoms
NCT05165992Phase 3Unknown
- Sponsor
- Hamad Medical Corporation
- Start
- Feb 2022
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of fentanyl in coronavirus disease 2019 (COVID-19), sponsored by Hamad Medical Corporation. Status: unknown.
02
Drugs
fentanyl
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05165992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05165992.